. . . . . . . "[17?-HSD type 3 (17?-HSD3) catalyses the reduction of the weakly androgenic androstenedione (adione) to testosterone, suggesting that specific inhibitors of 17?-HSD3 may have a role in the treatment of hormone-dependent prostate cancer and benign prostate hyperplasia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:13:29+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .